Item 1. FINANCIAL STATEMENTS
111K characters. Original on sec.gov ·
Item 1. FINANCIAL STATEMENTS
Dow Inc. and Subsidiaries
Consolidated Statements of Income
| Three Months Ended | ||||||||||||||
| In millions, except per share amounts (Unaudited) | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Net sales | $ | 11,851 | $ | 15,264 | ||||||||||
| Cost of sales | 10,629 | 12,402 | ||||||||||||
| Research and development expenses | 214 | 218 | ||||||||||||
| Selling, general and administrative expenses | 428 | 498 | ||||||||||||
| Amortization of intangibles | 81 | 88 | ||||||||||||
| Restructuring and asset related charges - net | 541 | 186 | ||||||||||||
| Equity in earnings (losses) of nonconsolidated affiliates | (48) | 174 | ||||||||||||
| Sundry income (expense) - net | 79 | 148 | ||||||||||||
| Interest income | 76 | 28 | ||||||||||||
| Interest expense and amortization of debt discount | 185 | 167 | ||||||||||||
| Income (loss) before income taxes | (120) | 2,055 | ||||||||||||
| Provision (credit) for income taxes | (47) | 503 | ||||||||||||
| Net income (loss) | (73) | 1,552 | ||||||||||||
| Net income (loss) attributable to noncontrolling interests | 20 | (17) | ||||||||||||
| Net income (loss) available for Dow Inc. common stockholders | $ | (93) | $ | 1,569 | ||||||||||
| Per common share data: | ||||||||||||||
| Earnings (loss) per common share - basic | $ | (0.13) | $ | 2.12 | ||||||||||
| Earnings (loss) per common share - diluted | $ | (0.13) | $ | 2.11 | ||||||||||
| Weighted-average common shares outstanding - basic | 708.2 | 734.6 | ||||||||||||
| Weighted-average common shares outstanding - diluted | 708.2 | 739.8 | ||||||||||||
| Depreciation | $ | 475 | $ | 491 | ||||||||||
| Capital expenditures | $ | 440 | $ | 315 |
See Notes to the Consolidated Financial Statements.
Dow Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
| Three Months Ended | ||||||||||||||
| In millions (Unaudited) | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Net income (loss) | $ | (73) | $ | 1,552 | ||||||||||
| Other comprehensive income (loss), net of tax | ||||||||||||||
| Unrealized gains (losses) on investments | 31 | (96) | ||||||||||||
| Cumulative translation adjustments | 101 | (164) | ||||||||||||
| Pension and other postretirement benefit plans | 6 | 109 | ||||||||||||
| Derivative instruments | (64) | 332 | ||||||||||||
| Total other comprehensive income | 74 | 181 | ||||||||||||
| Comprehensive income | 1 | 1,733 | ||||||||||||
| Comprehensive income (loss) attributable to noncontrolling interests, net of tax | 20 | (17) | ||||||||||||
| Comprehensive income (loss) attributable to Dow Inc. | $ | (19) | $ | 1,750 |
See Notes to the Consolidated Financial Statements.
Dow Inc. and Subsidiaries
Consolidated Balance Sheets
| In millions, except share amounts (Unaudited) | Mar 31, 2023 | Dec 31, 2022 | ||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 3,319 | $ | 3,886 | ||||
| Accounts and notes receivable: | ||||||||
| Trade (net of allowance for doubtful receivables - 2023: $110; 2022: $110) | 5,740 | 5,611 | ||||||
| Other | 2,072 | 2,144 | ||||||
| Inventories | 6,825 | 6,988 | ||||||
| Other current assets | 1,400 | 1,848 | ||||||
| Total current assets | 19,356 | 20,477 | ||||||
| Investments | ||||||||
| Investment in nonconsolidated affiliates | 1,508 | 1,589 | ||||||
| Other investments (investments carried at fair value - 2023: $1,806; 2022: $1,757) | 2,815 | 2,793 | ||||||
| Noncurrent receivables | 627 | 666 | ||||||
| Total investments | 4,950 | 5,048 | ||||||
| Property | ||||||||
| Property | 58,679 | 58,055 | ||||||
| Less: Accumulated depreciation | 38,356 | 37,613 | ||||||
| Net property | 20,323 | 20,442 | ||||||
| Other Assets | ||||||||
| Goodwill | 8,653 | 8,644 | ||||||
| Other intangible assets (net of accumulated amortization - 2023: $5,114; 2022: $5,022) | 2,336 | 2,442 | ||||||
| Operating lease right-of-use assets | 1,257 | 1,227 | ||||||
| Deferred income tax assets | 995 | 960 | ||||||
| Deferred charges and other assets | 1,446 | 1,363 | ||||||
| Total other assets | 14,687 | 14,636 | ||||||
| Total Assets | $ | 59,316 | $ | 60,603 | ||||
| Liabilities and Equity | ||||||||
| Current Liabilities | ||||||||
| Notes payable | $ | 278 | $ | 362 | ||||
| Long-term debt due within one year | 247 | 362 | ||||||
| Accounts payable: | ||||||||
| Trade | 4,575 | 4,940 | ||||||
| Other | 1,985 | 2,276 | ||||||
| Operating lease liabilities - current | 304 | 287 | ||||||
| Income taxes payable | 335 | 334 | ||||||
| Accrued and other current liabilities | 2,765 | 2,770 | ||||||
| Total current liabilities | 10,489 | 11,331 | ||||||
| Long-Term Debt | 14,739 | 14,698 | ||||||
| Other Noncurrent Liabilities | ||||||||
| Deferred income tax liabilities | 744 | 1,110 | ||||||
| Pension and other postretirement benefits - noncurrent | 3,799 | 3,808 | ||||||
| Asbestos-related liabilities - noncurrent | 844 | 857 | ||||||
| Operating lease liabilities - noncurrent | 1,007 | 997 | ||||||
| Other noncurrent obligations | 6,979 | 6,555 | ||||||
| Total other noncurrent liabilities | 13,373 | 13,327 | ||||||
| Stockholders’ Equity | ||||||||
| Common stock (authorized 5,000,000,000 shares of $0.01 par value each; issued 2023: 775,463,877 shares; 2022: 771,678,525 shares) | 8 | 8 | ||||||
| Additional paid-in capital | 8,607 | 8,540 | ||||||
| Retained earnings | 22,584 | 23,180 | ||||||
| Accumulated other comprehensive loss | (7,065) | (7,139) | ||||||
| Treasury stock at cost (2023: 68,149,070 shares; 2022: 66,798,605 shares) | (3,953) | (3,871) | ||||||
| Dow Inc.’s stockholders’ equity | 20,181 | 20,718 | ||||||
| Noncontrolling interests | 534 | 529 | ||||||
| Total equity | 20,715 | 21,247 | ||||||
| Total Liabilities and Equity | $ | 59,316 | $ | 60,603 |
See Notes to the Consolidated Financial Statements.
Dow Inc. and Subsidiaries
Consolidated Statements of Cash Flows
| In millions (Unaudited) | Three Months Ended | |||||||
| Mar 31, 2023 | Mar 31, 2022 | |||||||
| Operating Activities | ||||||||
| Net income (loss) | $ | (73) | $ | 1,552 | ||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 648 | 752 | ||||||
| Provision (credit) for deferred income tax | (418) | 253 | ||||||
| Earnings of nonconsolidated affiliates less than dividends received | 102 | 374 | ||||||
| Net periodic pension benefit cost (credit) | (23) | 7 | ||||||
| Pension contributions | (41) | (55) | ||||||
| Net gain on sales of assets, businesses and investments | (49) | (6) | ||||||
| Restructuring and asset related charges - net | 541 | 186 | ||||||
| Other net loss | 347 | 140 | ||||||
| Changes in assets and liabilities, net of effects of acquired and divested companies: | ||||||||
| Accounts and notes receivable | (68) | (741) | ||||||
| Inventories | 163 | (443) | ||||||
| Accounts payable | (631) | 86 | ||||||
| Other assets and liabilities, net | 33 | (493) | ||||||
| Cash provided by operating activities - continuing operations | 531 | 1,612 | ||||||
| Cash provided by (used for) operating activities - discontinued operations | 4 | (9) | ||||||
| Cash provided by operating activities | 535 | 1,603 | ||||||
| Investing Activities | ||||||||
| Capital expenditures | (440) | (315) | ||||||
| Investment in gas field developments | (55) | (37) | ||||||
| Purchases of previously leased assets | (2) | (2) | ||||||
| Proceeds from sales of property, businesses and consolidated companies, net of cash divested | 57 | 4 | ||||||
| Acquisitions of property and businesses, net of cash acquired | (23) | — | ||||||
| Investments in and loans to nonconsolidated affiliates | — | (6) | ||||||
| Distributions and loan repayments from nonconsolidated affiliates | 1 | — | ||||||
| Proceeds from sales of ownership interests in nonconsolidated affiliates | — | 11 | ||||||
| Purchases of investments | (165) | (148) | ||||||
| Proceeds from sales and maturities of investments | 512 | 141 | ||||||
| Other investing activities, net | (35) | (15) | ||||||
| Cash used for investing activities | (150) | (367) | ||||||
| Financing Activities | ||||||||
| Changes in short-term notes payable | (91) | (21) | ||||||
| Payments on short-term debt greater than three months | — | (14) | ||||||
| Proceeds from issuance of long-term debt | 13 | 16 | ||||||
| Payments on long-term debt | (156) | (25) | ||||||
| Collections on securitization programs | — | 141 | ||||||
| Purchases of treasury stock | (125) | (600) | ||||||
| Proceeds from issuance of stock | 55 | 35 | ||||||
| Employee taxes paid for share-based payment arrangements | (41) | (35) | ||||||
| Distributions to noncontrolling interests | (13) | (1) | ||||||
| Dividends paid to stockholders | (496) | (513) | ||||||
| Cash used for financing activities | (854) | (1,017) | ||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (41) | (45) | ||||||
| Summary | ||||||||
| Increase (decrease) in cash, cash equivalents and restricted cash | (510) | 174 | ||||||
| Cash, cash equivalents and restricted cash at beginning of period | 3,940 | 3,033 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 3,430 | $ | 3,207 | ||||
| Less: Restricted cash and cash equivalents, included in "Other current assets" | 111 | 64 | ||||||
| Cash and cash equivalents at end of period | $ | 3,319 | $ | 3,143 |
See Notes to the Consolidated Financial Statements.
Dow Inc. and Subsidiaries
Consolidated Statements of Equity
| Three Months Ended | ||||||||||||||
| In millions, except per share amounts (Unaudited) | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Common Stock | ||||||||||||||
| Balance at beginning and end of period | $ | 8 | $ | 8 | ||||||||||
| Additional Paid-in Capital | ||||||||||||||
| Balance at beginning of period | 8,540 | 8,151 | ||||||||||||
| Common stock issued/sold | 55 | 35 | ||||||||||||
| Stock-based compensation and allocation of ESOP shares | 56 | 35 | ||||||||||||
| Treasury stock issuances - compensation and benefit plans | (44) | (4) | ||||||||||||
| Balance at end of period | 8,607 | 8,217 | ||||||||||||
| Retained Earnings | ||||||||||||||
| Balance at beginning of period | 23,180 | 20,623 | ||||||||||||
| Net income (loss) available for Dow Inc. common stockholders | (93) | 1,569 | ||||||||||||
| Dividends to stockholders | (496) | (513) | ||||||||||||
| Other | (7) | (7) | ||||||||||||
| Balance at end of period | 22,584 | 21,672 | ||||||||||||
| Accumulated Other Comprehensive Loss | ||||||||||||||
| Balance at beginning of period | (7,139) | (8,977) | ||||||||||||
| Other comprehensive income | 74 | 181 | ||||||||||||
| Balance at end of period | (7,065) | (8,796) | ||||||||||||
| Unearned ESOP Shares | ||||||||||||||
| Balance at beginning of period | — | (15) | ||||||||||||
| Allocation of ESOP shares | — | 15 | ||||||||||||
| Balance at end of period | — | — | ||||||||||||
| Treasury Stock | ||||||||||||||
| Balance at beginning of period | (3,871) | (1,625) | ||||||||||||
| Treasury stock purchases | (126) | (600) | ||||||||||||
| Treasury stock issuances - compensation and benefit plans | 44 | 4 | ||||||||||||
| Balance at end of period | (3,953) | (2,221) | ||||||||||||
| Dow Inc.'s stockholders' equity | 20,181 | 18,880 | ||||||||||||
| Noncontrolling Interests | 534 | 545 | ||||||||||||
| Total Equity | $ | 20,715 | $ | 19,425 | ||||||||||
| Dividends declared per share of common stock | $ | 0.70 | $ | 0.70 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Income
| Three Months Ended | ||||||||||||||
| In millions (Unaudited) | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Net sales | $ | 11,851 | $ | 15,264 | ||||||||||
| Cost of sales | 10,628 | 12,398 | ||||||||||||
| Research and development expenses | 214 | 218 | ||||||||||||
| Selling, general and administrative expenses | 428 | 498 | ||||||||||||
| Amortization of intangibles | 81 | 88 | ||||||||||||
| Restructuring and asset related charges - net | 541 | 186 | ||||||||||||
| Equity in earnings (losses) of nonconsolidated affiliates | (48) | 174 | ||||||||||||
| Sundry income (expense) - net | 69 | 136 | ||||||||||||
| Interest income | 78 | 28 | ||||||||||||
| Interest expense and amortization of debt discount | 185 | 167 | ||||||||||||
| Income (loss) before income taxes | (127) | 2,047 | ||||||||||||
| Provision (credit) for income taxes | (47) | 503 | ||||||||||||
| Net income (loss) | (80) | 1,544 | ||||||||||||
| Net income (loss) attributable to noncontrolling interests | 20 | (17) | ||||||||||||
| Net income (loss) available for The Dow Chemical Company common stockholder | $ | (100) | $ | 1,561 | ||||||||||
| Depreciation | $ | 475 | $ | 491 | ||||||||||
| Capital expenditures | $ | 440 | $ | 315 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Comprehensive Income
| Three Months Ended | ||||||||||||||
| In millions (Unaudited) | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Net income (loss) | $ | (80) | $ | 1,544 | ||||||||||
| Other comprehensive income (loss), net of tax | ||||||||||||||
| Unrealized gains (losses) on investments | 31 | (96) | ||||||||||||
| Cumulative translation adjustments | 101 | (164) | ||||||||||||
| Pension and other postretirement benefit plans | 6 | 109 | ||||||||||||
| Derivative instruments | (64) | 332 | ||||||||||||
| Total other comprehensive income | 74 | 181 | ||||||||||||
| Comprehensive income (loss) | (6) | 1,725 | ||||||||||||
| Comprehensive income (loss) attributable to noncontrolling interests, net of tax | 20 | (17) | ||||||||||||
| Comprehensive income (loss) attributable to The Dow Chemical Company | $ | (26) | $ | 1,742 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Balance Sheets
| In millions, except share amounts (Unaudited) | Mar 31, 2023 | Dec 31, 2022 | ||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 3,319 | $ | 3,886 | ||||
| Accounts and notes receivable: | ||||||||
| Trade (net of allowance for doubtful receivables - 2023: $110; 2022: $110) | 5,740 | 5,611 | ||||||
| Other | 2,069 | 2,211 | ||||||
| Inventories | 6,825 | 6,988 | ||||||
| Other current assets | 1,377 | 1,815 | ||||||
| Total current assets | 19,330 | 20,511 | ||||||
| Investments | ||||||||
| Investment in nonconsolidated affiliates | 1,508 | 1,589 | ||||||
| Other investments (investments carried at fair value - 2023: $1,806; 2022: $1,757) | 2,815 | 2,793 | ||||||
| Noncurrent receivables | 607 | 650 | ||||||
| Total investments | 4,930 | 5,032 | ||||||
| Property | ||||||||
| Property | 58,679 | 58,055 | ||||||
| Less accumulated depreciation | 38,356 | 37,613 | ||||||
| Net property | 20,323 | 20,442 | ||||||
| Other Assets | ||||||||
| Goodwill | 8,653 | 8,644 | ||||||
| Other intangible assets (net of accumulated amortization - 2023: $5,114; 2022: $5,022) | 2,336 | 2,442 | ||||||
| Operating lease right-of-use assets | 1,257 | 1,227 | ||||||
| Deferred income tax assets | 995 | 960 | ||||||
| Deferred charges and other assets | 1,446 | 1,363 | ||||||
| Total other assets | 14,687 | 14,636 | ||||||
| Total Assets | $ | 59,270 | $ | 60,621 | ||||
| Liabilities and Equity | ||||||||
| Current Liabilities | ||||||||
| Notes payable | $ | 278 | $ | 362 | ||||
| Long-term debt due within one year | 247 | 362 | ||||||
| Accounts payable: | ||||||||
| Trade | 4,575 | 4,940 | ||||||
| Other | 1,985 | 2,349 | ||||||
| Operating lease liabilities - current | 304 | 287 | ||||||
| Income taxes payable | 335 | 334 | ||||||
| Accrued and other current liabilities | 2,623 | 2,613 | ||||||
| Total current liabilities | 10,347 | 11,247 | ||||||
| Long-Term Debt | 14,739 | 14,698 | ||||||
| Other Noncurrent Liabilities | ||||||||
| Deferred income tax liabilities | 744 | 1,110 | ||||||
| Pension and other postretirement benefits - noncurrent | 3,799 | 3,808 | ||||||
| Asbestos-related liabilities - noncurrent | 844 | 857 | ||||||
| Operating lease liabilities - noncurrent | 1,007 | 997 | ||||||
| Other noncurrent obligations | 6,837 | 6,415 | ||||||
| Total other noncurrent liabilities | 13,231 | 13,187 | ||||||
| Stockholder's Equity | ||||||||
| Common stock (authorized and issued 100 shares of $0.01 par value each) | — | — | ||||||
| Additional paid-in capital | 8,738 | 8,627 | ||||||
| Retained earnings | 18,746 | 19,472 | ||||||
| Accumulated other comprehensive loss | (7,065) | (7,139) | ||||||
| The Dow Chemical Company’s stockholder's equity | 20,419 | 20,960 | ||||||
| Noncontrolling interests | 534 | 529 | ||||||
| Total equity | 20,953 | 21,489 | ||||||
| Total Liabilities and Equity | $ | 59,270 | $ | 60,621 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Cash Flows
| In millions (Unaudited) | Three Months Ended | |||||||
| Mar 31, 2023 | Mar 31, 2022 | |||||||
| Operating Activities | ||||||||
| Net income (loss) | $ | (80) | $ | 1,544 | ||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 648 | 752 | ||||||
| Provision (credit) for deferred income tax | (418) | 253 | ||||||
| Earnings of nonconsolidated affiliates less than dividends received | 102 | 374 | ||||||
| Net periodic pension benefit cost (credit) | (23) | 7 | ||||||
| Pension contributions | (41) | (55) | ||||||
| Net gain on sales of assets, businesses and investments | (49) | (6) | ||||||
| Restructuring and asset related charges - net | 541 | 186 | ||||||
| Other net loss | 348 | 140 | ||||||
| Changes in assets and liabilities, net of effects of acquired and divested companies: | ||||||||
| Accounts and notes receivable | (68) | (741) | ||||||
| Inventories | 163 | (443) | ||||||
| Accounts payable | (631) | 86 | ||||||
| Other assets and liabilities, net | 42 | (486) | ||||||
| Cash provided by operating activities | 534 | 1,611 | ||||||
| Investing Activities | ||||||||
| Capital expenditures | (440) | (315) | ||||||
| Investment in gas field developments | (55) | (37) | ||||||
| Purchases of previously leased assets | (2) | (2) | ||||||
| Proceeds from sales of property, businesses and consolidated companies, net of cash divested | 57 | 4 | ||||||
| Acquisitions of property and businesses, net of cash acquired | (23) | — | ||||||
| Investments in and loans to nonconsolidated affiliates | — | (6) | ||||||
| Distributions and loan repayments from nonconsolidated affiliates | 1 | — | ||||||
| Proceeds from sales of ownership interests in nonconsolidated affiliates | — | 11 | ||||||
| Purchases of investments | (165) | (148) | ||||||
| Proceeds from sales and maturities of investments | 512 | 141 | ||||||
| Other investing activities, net | (35) | (15) | ||||||
| Cash used for investing activities | (150) | (367) | ||||||
| Financing Activities | ||||||||
| Changes in short-term notes payable | (91) | (21) | ||||||
| Payments on short-term debt greater than three months | — | (14) | ||||||
| Proceeds from issuance of long-term debt | 13 | 16 | ||||||
| Payments on long-term debt | (156) | (25) | ||||||
| Collections on securitization programs | — | 141 | ||||||
| Proceeds from issuance of stock | 55 | 35 | ||||||
| Employee taxes paid for share-based payment arrangements | (41) | (35) | ||||||
| Distributions to noncontrolling interests | (13) | (1) | ||||||
| Dividends paid to Dow Inc. | (620) | (1,121) | ||||||
| Cash used for financing activities | (853) | (1,025) | ||||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (41) | (45) | ||||||
| Summary | ||||||||
| Increase (decrease) in cash, cash equivalents and restricted cash | (510) | 174 | ||||||
| Cash, cash equivalents and restricted cash at beginning of period | 3,940 | 3,033 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 3,430 | $ | 3,207 | ||||
| Less: Restricted cash and cash equivalents, included in "Other current assets" | 111 | 64 | ||||||
| Cash and cash equivalents at end of period | $ | 3,319 | $ | 3,143 |
See Notes to the Consolidated Financial Statements.
The Dow Chemical Company and Subsidiaries
Consolidated Statements of Equity
| Three Months Ended | ||||||||||||||
| In millions (Unaudited) | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Common Stock | ||||||||||||||
| Balance at beginning and end of period | $ | — | $ | — | ||||||||||
| Additional Paid-in Capital | ||||||||||||||
| Balance at beginning of period | 8,627 | 8,159 | ||||||||||||
| Issuance of parent company stock - Dow Inc. | 55 | 35 | ||||||||||||
| Stock-based compensation and allocation of ESOP shares | 56 | 35 | ||||||||||||
| Balance at end of period | 8,738 | 8,229 | ||||||||||||
| Retained Earnings | ||||||||||||||
| Balance at beginning of period | 19,472 | 19,288 | ||||||||||||
| Net income (loss) available for The Dow Chemical Company common stockholder | (100) | 1,561 | ||||||||||||
| Dividends to Dow Inc. | (620) | (1,121) | ||||||||||||
| Other | (6) | (7) | ||||||||||||
| Balance at end of period | 18,746 | 19,721 | ||||||||||||
| Accumulated Other Comprehensive Loss | ||||||||||||||
| Balance at beginning of period | (7,139) | (8,977) | ||||||||||||
| Other comprehensive income | 74 | 181 | ||||||||||||
| Balance at end of period | (7,065) | (8,796) | ||||||||||||
| Unearned ESOP Shares | ||||||||||||||
| Balance at beginning of period | — | (15) | ||||||||||||
| Allocation of ESOP shares | — | 15 | ||||||||||||
| Balance at end of period | — | — | ||||||||||||
| The Dow Chemical Company's stockholder's equity | 20,419 | 19,154 | ||||||||||||
| Noncontrolling Interests | 534 | 545 | ||||||||||||
| Total Equity | $ | 20,953 | $ | 19,699 |
See Notes to the Consolidated Financial Statements.
| Dow Inc. and Subsidiaries The Dow Chemical Company and Subsidiaries (Unaudited) |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
Table of Contents
NOTE 1 – CONSOLIDATED FINANCIAL STATEMENTS
Basis of Presentation
Dow Inc. is the direct parent company of The Dow Chemical Company and its consolidated subsidiaries ("TDCC" and together with Dow Inc., "Dow" or the "Company"). The unaudited interim consolidated financial statements of Dow Inc. and TDCC were prepared in accordance with accounting principles generally accepted in the United States of America and reflect all adjustments (including normal recurring accruals) which, in the opinion of management, are considered necessary for the fair presentation of the results for the periods presented. These statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the combined Dow Inc. and TDCC Annual Report on Form 10-K for the year ended December 31, 2022 ("2022 10-K").
As a result of the parent/subsidiary relationship between Dow Inc. and TDCC, and considering that the financial statements and disclosures of each company are substantially similar, the companies are filing a combined report for this Quarterly Report on Form 10-Q. The information reflected in the report is equally applicable to both Dow Inc. and TDCC, except where otherwise noted. Transactions between TDCC and Dow Inc. are treated as related party transactions for TDCC.
Except as otherwise indicated by the context, the term "Union Carbide" means Union Carbide Corporation and the term "Dow Silicones" means Dow Silicones Corporation, both wholly owned subsidiaries of the Company.
NOTE 2 – RECENT ACCOUNTING GUIDANCE
Recently Adopted Accounting Guidance
In the first quarter of 2023, the Company adopted the interim period disclosure requirements of Accounting Standards Update ("ASU") 2022-04, "Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations." The ASU, issued in September 2022, requires disclosures intended to enhance the transparency of supplier finance programs. Specifically, the amendments require buyers in a supplier finance program to disclose sufficient information about the program to allow a user of financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. The amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for disclosure of rollforward information, which is required to be disclosed annually and is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The amendments should be applied retrospectively to each period in which a balance sheet is presented, except for disclosure of rollforward information, which should be applied prospectively. The Company expects to early adopt the annual requirement to disclose rollforward information prospectively beginning in the 2023 annual financial statements. See Note 5 for disclosures related to the Company's supplier finance program.
Accounting Guidance Issued But Not Adopted at March 31, 2023
In March 2023, the Financial Accounting Standards Board issued ASU 2023-02, "Investments — Equity Method and Joint Ventures (Topic 323): Accounting for Investments in Tax Credit Structures Using the Proportional Amortization Method." The amendments permit reporting entities to elect to account for their tax equity investments using the proportional amortization method if certain conditions are met. Under the proportional amortization method, an entity amortizes the initial cost of the investment in proportion to the income tax credits and other income tax benefits received and recognizes the net amortization and income tax credits and other income tax benefits in the income statement as a component of income tax expense (benefit). The amendments also require certain disclosures in annual and interim reporting periods about an entity's tax credit programs. The new standard is effective for public companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and the amendments must be applied on either a modified retrospective or a retrospective basis. Early adoption is permitted. The Company is currently evaluating early adoption of the new guidance in 2023 and the adoption is not expected to have a material impact on the consolidated financial statements.
NOTE 3 – REVENUE
Revenue Recognition
The majority of the Company's revenue is derived from product sales. The Company's revenue related to product sales was 99 percent for the three months ended March 31, 2023 and March 31, 2022. The remaining sales were primarily related to the Company's insurance operations and licensing of patents and technologies. Product sales consist of sales of the Company's products to manufacturers and distributors. The Company considers order confirmations or purchase orders, which in some cases are governed by master supply agreements, to be contracts with a customer. The Company enters into licensing arrangements in which it licenses certain rights of its patents and technology to customers. Revenue from the Company’s licenses for patents and technology is derived from sales-based royalties and licensing arrangements based on billing schedules established in each contract.
Remaining Performance Obligations
Remaining performance obligations represent the transaction price allocated to unsatisfied or partially unsatisfied performance obligations. At March 31, 2023, the Company had unfulfilled performance obligations of $963 million ($840 million at December 31, 2022) related to the licensing of technology. The Company expects revenue to be recognized for the remaining performance obligations over the next seven years.
The remaining performance obligations are for product sales that have expected durations of one year or less, product sales of materials delivered through a pipeline for which the Company has elected the right to invoice practical expedient, or variable consideration attributable to royalties for licenses of patents and technology. The Company has received advance payments from customers related to long-term supply agreements that are deferred and recognized over the life of the contract, with remaining contract terms that range up to 17 years. The Company will have rights to future consideration for revenue recognized when product is delivered to the customer. These payments are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the consolidated balance sheets.
Disaggregation of Revenue
The Company disaggregates its revenue from contracts with customers by operating segment and business, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows. See details in the tables below:
| Net Trade Sales by Segment and Business | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Hydrocarbons & Energy | $ | 1,874 | $ | 2,416 | ||||||||||
| Packaging and Specialty Plastics | 4,240 | 5,211 | ||||||||||||
| Packaging & Specialty Plastics | $ | 6,114 | $ | 7,627 | ||||||||||
| Industrial Solutions | $ | 1,139 | $ | 1,515 | ||||||||||
| Polyurethanes & Construction Chemicals | 2,234 | 3,005 | ||||||||||||
| Other | 5 | 4 | ||||||||||||
| Industrial Intermediates & Infrastructure | $ | 3,378 | $ | 4,524 | ||||||||||
| Coatings & Performance Monomers | $ | 858 | $ | 1,075 | ||||||||||
| Consumer Solutions | 1,418 | 1,974 | ||||||||||||
| Performance Materials & Coatings | $ | 2,276 | $ | 3,049 | ||||||||||
| Corporate | $ | 83 | $ | 64 | ||||||||||
| Total | $ | 11,851 | $ | 15,264 |
| Net Trade Sales by Geographic Region | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| U.S. & Canada | $ | 4,450 | $ | 5,537 | ||||||||||
| EMEAI 1 | 4,053 | 5,512 | ||||||||||||
| Asia Pacific | 2,047 | 2,753 | ||||||||||||
| Latin America | 1,301 | 1,462 | ||||||||||||
| Total | $ | 11,851 | $ | 15,264 |
1.Europe, Middle East, Africa and India.
Contract Assets and Liabilities
The Company receives payments from customers based upon contractual billing schedules. Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts related to the Company's contractual right to consideration for completed performance obligations not yet invoiced. Contract liabilities include payments received in advance of performance under the contract and are recognized in revenue when the performance obligations are met. "Contract liabilities - current" primarily reflects deferred revenue from prepayments from customers for product to be delivered in 12 months or less and royalty payments that are deferred and will be recognized in 12 months or less. "Contract liabilities - noncurrent" includes advance payments that the Company has received from customers related to long-term supply agreements and royalty payments that are deferred and recognized over the life of the contract.
Revenue recognized in the first three months of 2023 from amounts included in contract liabilities at the beginning of the period was approximately $40 million (approximately $65 million in the first three months of 2022). In the first three months of 2023, the amount of contract assets reclassified to receivables as a result of the right to the transaction consideration becoming unconditional was approximately $30 million (insignificant in the first three months of 2022).
The following table summarizes contract assets and liabilities at March 31, 2023 and December 31, 2022:
| Contract Assets and Liabilities | Balance Sheet Classification | Mar 31, 2023 | Dec 31, 2022 | ||||||||
| In millions | |||||||||||
| Accounts and notes receivable - trade | Accounts and notes receivable - trade | $ | 5,740 | $ | 5,611 | ||||||
| Contract assets - current | Other current assets | $ | 21 | $ | 48 | ||||||
| Contract assets - noncurrent | Deferred charges and other assets | $ | 16 | $ | 16 | ||||||
| Contract liabilities - current | Accrued and other current liabilities | $ | 293 | $ | 275 | ||||||
| Contract liabilities - noncurrent | Other noncurrent obligations | $ | 1,740 | $ | 1,725 |
NOTE 4 – RESTRUCTURING AND ASSET RELATED CHARGES - NET
Charges for restructuring programs and other asset related charges, which includes asset impairments, are recorded in "Restructuring and asset related charges - net" in the consolidated statements of income. For additional information on the Company's restructuring programs, see Note 5 to the Consolidated Financial Statements included in the 2022 10-K.
2023 Restructuring Program
On January 25, 2023, the Dow Inc. Board of Directors ("Board") approved restructuring actions to achieve the Company's structural cost improvement initiatives in response to the continued economic impact from the global recessionary environment and to enhance its agility and long-term competitiveness across the economic cycle. As a result of these actions the Company recorded pretax restructuring charges of $541 million in the first quarter of 2023. These actions are expected to be substantially complete by the end of 2024. The following table summarizes the activities related to the 2023 Restructuring Program, including segment information:
| 2023 Restructuring Program | Severance and Related Benefit Costs | Asset Write-downs and Write-offs | Total | |||||||||||
| In millions | ||||||||||||||
| Packaging & Specialty Plastics | $ | — | $ | 1 | $ | 1 | ||||||||
| Industrial Intermediates & Infrastructure | — | 40 | 40 | |||||||||||
| Performance Materials & Coatings | — | 49 | 49 | |||||||||||
| Corporate | 344 | 107 | 451 | |||||||||||
| Total restructuring charges | $ | 344 | $ | 197 | $ | 541 | ||||||||
| Charges against the reserve | — | (197) | (197) | |||||||||||
| Cash payments | (11) | — | (11) | |||||||||||
| Reserve balance at Mar 31, 2023 | $ | 333 | $ | — | $ | 333 | ||||||||
At March 31, 2023, $256 million of the reserve balance was included in "Accrued and other current liabilities" and $77 million was included in "Other noncurrent obligations" in the consolidated balance sheets.
Severance and Related Benefit Costs
Severance benefits are provided to employees primarily under Dow's ongoing benefit arrangements and are accrued against the Corporate segment once management commits to a plan of termination. The 2023 Restructuring Program included a charge for severance and related benefit costs of $344 million for a global workforce reduction of approximately 2,000 employees. A majority of separations are intended to occur by the end of the second quarter of 2023 with the remaining occurring primarily through the end of 2024.
Asset Write-downs and Write-offs
The restructuring charge related to the write-down and write-off of assets in the first quarter of 2023 totaled $197 million. Details regarding the asset write-downs and write-offs are as follows:
-
Industrial Intermediates & Infrastructure charges relate to the shutdown of certain polyurethanes assets and the write-off of other assets. The majority of the impacted facilities are expected to be shutdown by the end of 2024.
-
Performance Materials & Coatings recorded charges to rationalize its asset footprint by shutting down certain coatings assets. These facilities are expected to be shutdown by the end of 2024.
-
Corporate recorded charges related to the write-down of Company owned and leased, non-manufacturing facilities, primarily related to office space rationalization.
Restructuring implementation costs, primarily decommissioning and demolition activities related to asset actions, and costs associated with the Company's efficiency actions, are expected to result in additional cash expenditures of approximately $425 million, primarily through the end of 2024.
2022 Asset Related Charges
In the first quarter of 2022, the Company recorded pretax asset related charges of $186 million due to the Russia and Ukraine conflict and the expectation that certain assets will not be recoverable. These charges included the write-down of inventory, the recording of bad debt reserves and the impairment of other assets. Asset related charges by segment were as follows: $31 million in Packaging & Specialty Plastics, $109 million in Industrial Intermediates & Infrastructure, $16 million in Performance Materials & Coatings and $30 million in Corporate.
NOTE 5 – SUPPLEMENTARY INFORMATION
| Dow Inc. Sundry Income (Expense) – Net | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Non-operating pension and other postretirement benefit plan net credits 1 | $ | 96 | $ | 89 | ||||||||||
| Foreign exchange gains (losses) 2 | (102) | 2 | ||||||||||||
| Gain on sales of other assets and investments 3 | 65 | 31 | ||||||||||||
| Asset impairments and related costs 4 | (18) | — | ||||||||||||
| Indemnification and other transaction related costs 5 | 9 | 12 | ||||||||||||
| Other - net | 29 | 14 | ||||||||||||
| Total sundry income (expense) – net | $ | 79 | $ | 148 |
1.See Note 12 for additional information.
2.Foreign exchange losses for the three months ended March 31, 2023 relate primarily to exposures in the Argentinian peso.
3.Includes gains associated with the sale of shares of a previously impaired equity method investment.
4.Certain obligations associated with a previously impaired equity method investment.
5.Primarily related to charges associated with agreements entered into with DuPont and Corteva as part of the separation and distribution.
Sundry income (expense) - net for TDCC for the three months ended March 31, 2023 and 2022 is substantially the same as that of Dow Inc. and therefore is not disclosed separately.
Supplier Finance Program
The Company facilitates a supply chain financing (“SCF”) program in the ordinary course of business in order to extend payment terms with vendors. Under the terms of this program, a vendor can voluntarily enter into an agreement with a participating financial intermediary to sell its receivables due from the Company. The vendor receives payment from the financial intermediary, and the Company pays the financial intermediary on the terms originally negotiated with the vendor, which generally range from 90 to 120 days. The vendor negotiates the terms of the agreements directly with the financial intermediary and the Company is not a party to that agreement. The financial intermediary may allow the participating vendor to utilize the Company’s creditworthiness in establishing credit spreads and associated costs, which may provide the vendor with more favorable terms than they would be able to secure on their own. The Company does not provide guarantees related to the SCF program. At March 31, 2023, outstanding obligations confirmed as valid under the SCF program were $290 million ($267 million at December 31, 2022), included in “Accounts payable – Trade” in the consolidated balance sheets.
NOTE 6 - EARNINGS PER SHARE CALCULATIONS
The following tables provide earnings per share calculations for Dow Inc. for the three months ended March 31, 2023 and 2022. Earnings per share of TDCC is not presented as this information is not required in financial statements of wholly owned subsidiaries.
| Net Income (Loss) for Earnings Per Share Calculations | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Net income (loss) | $ | (73) | $ | 1,552 | ||||||||||
| Net income (loss) attributable to noncontrolling interests | 20 | (17) | ||||||||||||
| Net income attributable to participating securities 1 | 3 | 8 | ||||||||||||
| Net income (loss) attributable to common stockholders | $ | (96) | $ | 1,561 |
| Earnings (Loss) Per Share - Basic and Diluted | Three Months Ended | |||||||||||||
| Dollars per share | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Earnings (loss) per common share - basic | $ | (0.13) | $ | 2.12 | ||||||||||
| Earnings (loss) per common share - diluted | $ | (0.13) | $ | 2.11 |
| Share Count Information | Three Months Ended | |||||||||||||
| Shares in millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Weighted-average common shares outstanding - basic | 708.2 | 734.6 | ||||||||||||
| Plus dilutive effect of equity compensation plans 2 | — | 5.2 | ||||||||||||
| Weighted-average common shares outstanding - diluted | 708.2 | 739.8 | ||||||||||||
| Stock options and restricted stock units excluded from EPS calculations 3 | 22.1 | 6.8 |
1.Restricted stock units are considered participating securities due to the Company's practice of paying dividend equivalents on unvested shares.
2.The three months ended March 31, 2023 reflect a net loss, and as such, the basic share count was used for purposes of calculating earnings per share on a diluted basis.
3.These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.
NOTE 7 – INVENTORIES
The following table provides a breakdown of inventories:
| Inventories | Mar 31, 2023 | Dec 31, 2022 | ||||||
| In millions | ||||||||
| Finished goods | $ | 3,974 | $ | 4,150 | ||||
| Work in process | 1,458 | 1,476 | ||||||
| Raw materials | 867 | 954 | ||||||
| Supplies | 911 | 892 | ||||||
| Total | $ | 7,210 | $ | 7,472 | ||||
| Adjustment of inventories to the LIFO basis | (385) | (484) | ||||||
| Total inventories | $ | 6,825 | $ | 6,988 |
NOTE 8 – COMMITMENTS AND CONTINGENCIES
A summary of the Company's commitments and contingencies can be found in Note 15 to the Consolidated Financial Statements included in the 2022 10-K, which is incorporated by reference herein.
Environmental Matters
Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated, based on current law and existing technologies. At March 31, 2023, the Company had accrued obligations of $1,233 million for probable environmental remediation and restoration costs ($1,192 million at December 31, 2022), including $254 million for the remediation of Superfund sites ($244 million at December 31, 2022). This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the Company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to approximately two times that amount. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company's results of operations, financial condition and cash flows. It is the opinion of the Company’s management, however, that the possibility is remote that costs in excess of the range disclosed will have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration. As new or additional information becomes available and/or certain spending trends become known, management will evaluate such information in determination of the current estimate of environmental liability.
Litigation
Asbestos-Related Matters of Union Carbide Corporation
Each quarter, Union Carbide reviews asbestos-related claims filed, settled and dismissed, as well as average settlement and resolution costs by disease category. Union Carbide also considers additional quantitative and qualitative factors such as the nature of pending claims, trial experience of Union Carbide and other asbestos defendants, current spending for defense and processing costs, significant appellate rulings and legislative developments, trends in the tort system, and their respective effects on expected future resolution costs. Union Carbide's management considers these factors in conjunction with the most recent actuarial study and determines whether a change in the estimate is warranted. Based on Union Carbide's review of 2023 activity, it was determined that no adjustment to the accrual was required at March 31, 2023.
Union Carbide’s total asbestos-related liability for pending and future claims and defense and processing costs was $929 million at March 31, 2023 ($947 million at December 31, 2022). At March 31, 2023, approximately 25 percent of the recorded claim liability related to pending claims and approximately 75 percent related to future claims.
Groundwater Contamination
The Company is the subject of various complaints related to alleged groundwater contamination based on decades-old sales and applications of certain agricultural chemical products ("Legacy Liabilities"). The costs associated with these Legacy Liabilities were previously covered by insurance policies that have since been depleted. In the first quarter of 2023, the Company completed a study of the Legacy Liabilities now deemed to be probable and estimable based on the public reporting of sampling data and historical information to develop a reasonable estimate of the cost of pending and future claims. As a result, the Company recorded a pretax charge of $177 million, included in "Cost of sales" in the consolidated statements of income and related to Industrial Intermediates & Infrastructure. At March 31, 2023, the total liability related to such alleged Legacy Liabilities settlements was $237 million, which was included in “Accrued and other current liabilities” and "Other noncurrent obligations" in the consolidated balance sheets.
Indemnifications with Corning Incorporated
The Company had indemnification assets with Corning Incorporated of $99 million at March 31, 2023 ($98 million at December 31, 2022) related to the 2016 ownership restructure of Dow Silicones, which were included in "Noncurrent receivables" in the consolidated balance sheets.
Gain Contingency - Dow v. Nova Chemicals Corporation Ethylene Asset Matter
As a result of a 2019 damages judgment related to the ethylene asset matter, Nova was ordered to pay the Company $1.43 billion Canadian dollars (equivalent to approximately $1.08 billion U.S. dollars), for which the Company received payment in October 2019 and March 2020. At March 31, 2023, $323 million ($323 million at December 31, 2022) was included in "Other noncurrent obligations" in the Company's consolidated balance sheets related to the disputed portion of the damages judgment.
NOTE 9 - LEASES
For additional information on the Company's leases, see Note 16 to the Consolidated Financial Statements included in the 2022 10-K.
The components of lease cost for operating and finance leases for the three months ended March 31, 2023 and 2022 were as follows:
| Lease Cost | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Operating lease cost | $ | 98 | $ | 97 | ||||||||||
| Finance lease cost | ||||||||||||||
| Amortization of right-of-use assets - finance | $ | 26 | $ | 26 | ||||||||||
| Interest on lease liabilities - finance | 8 | 8 | ||||||||||||
| Total finance lease cost | $ | 34 | $ | 34 | ||||||||||
| Short-term lease cost | 66 | 59 | ||||||||||||
| Variable lease cost | 181 | 115 | ||||||||||||
| Sublease income | (2) | (3) | ||||||||||||
| Total lease cost | $ | 377 | $ | 302 |
The following table provides supplemental cash flow and other information related to leases:
| Other Lease Information | Three Months Ended | |||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||
| Cash paid for amounts included in the measurement of lease liabilities: | ||||||||
| Operating cash flows for operating leases | $ | 105 | $ | 101 | ||||
| Operating cash flows for finance leases | $ | 8 | $ | 8 | ||||
| Financing cash flows for finance leases | $ | 28 | $ | 22 | ||||
| Right-of-use assets obtained in exchange for lease obligations: | ||||||||
| Operating leases | $ | 99 | $ | 16 | ||||
| Finance leases | $ | 6 | $ | 17 |
NOTE 10 – ACCUMULATED OTHER COMPREHENSIVE LOSS
The changes in each component of accumulated other comprehensive loss ("AOCL") for the three months ended March 31, 2023 and 2022 were as follows:
| Accumulated Other Comprehensive Loss | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Unrealized Gains (Losses) on Investments | ||||||||||||||
| Beginning balance | $ | (253) | $ | 59 | ||||||||||
| Unrealized gains (losses) on investments | 30 | (121) | ||||||||||||
| Tax (expense) benefit | — | 24 | ||||||||||||
| Net unrealized gains (losses) on investments | 30 | (97) | ||||||||||||
| (Gains) losses reclassified from AOCL to net income (loss) 1 | 1 | 1 | ||||||||||||
| Tax expense (benefit) 2 | — | — | ||||||||||||
| Net (gains) losses reclassified from AOCL to net income (loss) | 1 | 1 | ||||||||||||
| Other comprehensive income (loss), net of tax | 31 | (96) | ||||||||||||
| Ending balance | $ | (222) | $ | (37) | ||||||||||
| Cumulative Translation Adjustment | ||||||||||||||
| Beginning balance | $ | (1,934) | $ | (1,355) | ||||||||||
| Gains (losses) on foreign currency translation | 84 | (165) | ||||||||||||
| Tax (expense) benefit | 2 | 13 | ||||||||||||
| Net gains (losses) on foreign currency translation | 86 | (152) | ||||||||||||
| (Gains) losses reclassified from AOCL to net income (loss) 3 | 15 | (12) | ||||||||||||
| Other comprehensive income (loss), net of tax | 101 | (164) | ||||||||||||
| Ending balance | $ | (1,833) | $ | (1,519) | ||||||||||
| Pension and Other Postretirement Benefits | ||||||||||||||
| Beginning balance | $ | (4,877) | $ | (7,334) | ||||||||||
| Gains (losses) arising during the period | 2 | 2 | ||||||||||||
| Amortization of net loss and prior service credits reclassified from AOCL to net income (loss) 4 | 3 | 157 | ||||||||||||
| Tax expense (benefit) 2 | 1 | (50) | ||||||||||||
| Net loss and prior service credits reclassified from AOCL to net income (loss) | 4 | 107 | ||||||||||||
| Other comprehensive income (loss), net of tax | 6 | 109 | ||||||||||||
| Ending balance | $ | (4,871) | $ | (7,225) | ||||||||||
| Derivative Instruments | ||||||||||||||
| Beginning balance | $ | (75) | $ | (347) | ||||||||||
| Gains (losses) on derivative instruments | (183) | 420 | ||||||||||||
| Tax (expense) benefit | 33 | (56) | ||||||||||||
| Net gains (losses) on derivative instruments | (150) | 364 | ||||||||||||
| (Gains) losses reclassified from AOCL to net income (loss) 5 | 109 | (34) | ||||||||||||
| Tax expense (benefit) 2 | (23) | 2 | ||||||||||||
| Net (gains) losses reclassified from AOCL to net income (loss) | 86 | (32) | ||||||||||||
| Other comprehensive income (loss), net of tax | (64) | 332 | ||||||||||||
| Ending balance | $ | (139) | $ | (15) | ||||||||||
| Total AOCL ending balance | $ | (7,065) | $ | (8,796) |
1.Reclassified to "Net sales" and "Sundry income (expense) - net."
2.Reclassified to "Provision (credit) for income taxes."
3.Reclassified to "Sundry income (expense) - net."
4.These AOCL components are included in the computation of net periodic benefit cost (credit) of the Company's defined benefit pension and other postretirement benefit plans. See Note 12 for additional information.
5.Reclassified to "Cost of sales," "Sundry income (expense) - net" and "Interest expense and amortization of debt discount."
NOTE 11 – NONCONTROLLING INTERESTS
Ownership interests in the Company's subsidiaries held by parties other than the Company are presented separately from the Company's equity in the consolidated balance sheets as "Noncontrolling interests." The amount of consolidated net income attributable to the Company and the noncontrolling interests are both presented on the face of the consolidated statements of income.
The following table summarizes the activity for equity attributable to noncontrolling interests for the three months ended March 31, 2023 and 2022:
| Noncontrolling Interests | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Balance at beginning of period | $ | 529 | $ | 574 | ||||||||||
| Net income (loss) attributable to noncontrolling interests 1 | 20 | (17) | ||||||||||||
| Distributions to noncontrolling interests | (13) | (1) | ||||||||||||
| Cumulative translation adjustments | (3) | (11) | ||||||||||||
| Other | 1 | — | ||||||||||||
| Balance at end of period | $ | 534 | $ | 545 |
1.The first quarter of 2022 includes the portion of asset related charges attributable to noncontrolling interests related to a joint venture in Russia. See Note 4 for additional information.
NOTE 12 – PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS
A summary of the Company's pension and other postretirement benefit plans can be found in Note 19 to the Consolidated Financial Statements included in the 2022 10-K. The following table provides the components of the Company's net periodic benefit cost (credit) for all significant plans:
| Net Periodic Benefit Cost (Credit) for All Significant Plans | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Defined Benefit Pension Plans | ||||||||||||||
| Service cost | $ | 70 | $ | 99 | ||||||||||
| Interest cost | 279 | 171 | ||||||||||||
| Expected return on plan assets | (389) | (424) | ||||||||||||
| Amortization of prior service credit | (7) | (6) | ||||||||||||
| Amortization of net loss | 24 | 167 | ||||||||||||
| Net periodic benefit cost (credit) | $ | (23) | $ | 7 | ||||||||||
| Other Postretirement Benefit Plans | ||||||||||||||
| Service cost | $ | 1 | $ | 1 | ||||||||||
| Interest cost | 11 | 7 | ||||||||||||
| Amortization of net gain | (14) | (4) | ||||||||||||
| Net periodic benefit cost (credit) | $ | (2) | $ | 4 |
Net periodic benefit cost (credit), other than the service cost component, is included in "Sundry income (expense) - net" in the consolidated statements of income.
NOTE 13 – STOCK-BASED COMPENSATION
A summary of the Company's stock-based compensation plans can be found in Note 20 to the Consolidated Financial Statements included in the 2022 10-K.
Stock Incentive Plan
The Company grants stock-based compensation to employees and non-employee directors under the 2019 Stock Incentive Plan, as amended. Most of the Company's stock-based compensation awards are granted in the first quarter of each year.
In the first quarter of 2023, Dow Inc. granted the following stock-based compensation awards to employees:
-
1.1 million stock options with a weighted-average exercise price of $59.08 per share and a weighted-average fair value of $12.13 per share;
-
1.8 million restricted stock units with a weighted-average fair value of $59.03 per share; and
-
1.2 million performance stock units with a weighted-average fair value of $64.04 per share.
Employee Stock Purchase Plan
The Dow Inc. 2021 Employee Stock Purchase Plan (the "2021 ESPP") was adopted by the Dow Inc. Board on February 11, 2021, and approved by stockholders at the Company's annual meeting on April 15, 2021. Under the 2023 annual offering of the 2021 ESPP, most employees will be eligible to purchase shares of common stock of Dow Inc. valued at up to 10 percent of their annual total base salary or wages. The number of shares purchased is determined using the amount contributed by the employee divided by the plan price. The plan price of the stock is equal to 85 percent of the fair market value (closing price) of the common stock at May 1, 2023 (beginning) or November 3, 2023 (ending) of the offering period, whichever is lower.
NOTE 14 – FINANCIAL INSTRUMENTS
A summary of the Company's financial instruments, risk management policies, derivative instruments and hedging activities can be found in Note 21 to the Consolidated Financial Statements included in the 2022 10-K.
The following table summarizes the fair value of financial instruments at March 31, 2023 and December 31, 2022:
| Fair Value of Financial Instruments | Mar 31, 2023 | Dec 31, 2022 | ||||||||||||||||||||||||
| In millions | Cost | Gain | Loss | Fair Value | Cost | Gain | Loss | Fair Value | ||||||||||||||||||
| Cash equivalents: | ||||||||||||||||||||||||||
| Held-to-maturity securities 1 | $ | 714 | $ | — | $ | — | $ | 714 | $ | 872 | $ | — | $ | — | $ | 872 | ||||||||||
| Money market funds | 1,273 | — | — | 1,273 | 355 | — | — | 355 | ||||||||||||||||||
| Total cash equivalents | $ | 1,987 | $ | — | $ | — | $ | 1,987 | $ | 1,227 | $ | — | $ | — | $ | 1,227 | ||||||||||
| Marketable securities 2 | $ | 610 | $ | 9 | $ | — | $ | 619 | $ | 927 | $ | 12 | $ | — | $ | 939 | ||||||||||
| Other investments: | ||||||||||||||||||||||||||
| Debt securities: | ||||||||||||||||||||||||||
| Government debt 3 | $ | 762 | $ | 1 | $ | (122) | $ | 641 | $ | 754 | $ | 1 | $ | (133) | $ | 622 | ||||||||||
| Corporate bonds | 1,272 | 9 | (134) | 1,147 | 1,274 | 10 | (159) | 1,125 | ||||||||||||||||||
| Total debt securities | $ | 2,034 | $ | 10 | $ | (256) | $ | 1,788 | $ | 2,028 | $ | 11 | $ | (292) | $ | 1,747 | ||||||||||
| Equity securities 4 | 5 | 13 | — | 18 | 5 | 5 | — | 10 | ||||||||||||||||||
| Total other investments | $ | 2,039 | $ | 23 | $ | (256) | $ | 1,806 | $ | 2,033 | $ | 16 | $ | (292) | $ | 1,757 | ||||||||||
| Total cash equivalents, marketable securities and other investments | $ | 4,636 | $ | 32 | $ | (256) | $ | 4,412 | $ | 4,187 | $ | 28 | $ | (292) | $ | 3,923 | ||||||||||
| Long-term debt including debt due within one year 5 | $ | (14,986) | $ | 1,389 | $ | (642) | $ | (14,239) | $ | (15,060) | $ | 1,683 | $ | (498) | $ | (13,875) | ||||||||||
| Derivatives relating to: | ||||||||||||||||||||||||||
| Interest rates 6 | $ | — | $ | 2 | $ | — | $ | 2 | $ | — | $ | 105 | $ | — | $ | 105 | ||||||||||
| Foreign currency | — | 66 | (17) | 49 | — | 115 | (30) | 85 | ||||||||||||||||||
| Commodities 6 | — | 24 | (30) | (6) | — | 72 | (61) | 11 | ||||||||||||||||||
| Total derivatives | $ | — | $ | 92 | $ | (47) | $ | 45 | $ | — | $ | 292 | $ | (91) | $ | 201 |
1.The Company's held-to-maturity securities primarily included treasury bills and time deposits.
2.The Company’s investments in marketable securities are included in “Other current assets” in the consolidated balance sheets.
3.U.S. Treasury obligations, U.S. agency obligations, U.S. agency mortgage-backed securities and other municipalities’ obligations.
4.Equity securities with a readily determinable fair value.
5.Cost includes fair value hedge adjustment gains of $49 million at March 31, 2023 and $46 million at December 31, 2022 on $2,729 million of debt at March 31, 2023 and $2,279 million of debt at December 31, 2022.
6.Presented net of cash collateral where master netting arrangements allow.
Cost approximates fair value for all other financial instruments.
Debt Securities
The Company's investments in debt securities are primarily classified as available-for-sale. The following table provides investing results from available-for-sale securities for the three months ended March 31, 2023 and 2022:
| Investing Results | Three Months Ended | |||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||
| Proceeds from sales of available-for-sale securities | $ | 146 | $ | 113 | ||||
| Gross realized gains | $ | 8 | $ | 12 | ||||
| Gross realized losses | $ | (9) | $ | (13) |
The following table summarizes contractual maturities of the Company's investments in debt securities:
| Contractual Maturities of Debt Securities at Mar 31, 2023 | Cost | Fair Value | ||||||
| In millions | ||||||||
| Within one year | $ | 78 | $ | 76 | ||||
| One to five years | 894 | 814 | ||||||
| Six to ten years | 550 | 479 | ||||||
| After ten years | 512 | 419 | ||||||
| Total | $ | 2,034 | $ | 1,788 |
Equity Securities
There were no material adjustments to the carrying value of the not readily determinable investments for impairment or observable price changes for the three months ended March 31, 2023. There was $8 million of net unrealized gains recognized in earnings on equity securities for the three months ended March 31, 2023 ($3 million net unrealized loss for the three months ended March 31, 2022).
| Investments in Equity Securities | Mar 31, 2023 | Dec 31, 2022 | ||||||
| In millions | ||||||||
| Readily determinable fair value | $ | 18 | $ | 10 | ||||
| Not readily determinable fair value | $ | 178 | $ | 186 |
Derivative Instruments
The notional amounts of the Company's derivative instruments at March 31, 2023 and December 31, 2022 were as follows:
| Notional Amounts 1 | Mar 31, 2023 | Dec 31, 2022 | ||||||
| In millions | ||||||||
| Derivatives designated as hedging instruments: | ||||||||
| Interest rate contracts | $ | 450 | $ | 1,500 | ||||
| Foreign currency contracts | $ | 2,141 | $ | 2,408 | ||||
| Derivatives not designated as hedging instruments: | ||||||||
| Interest rate contracts | $ | 46 | $ | 3 | ||||
| Foreign currency contracts | $ | 12,150 | $ | 8,837 |
1.Notional amounts represent the absolute value of open derivative positions at the end of the period. Multi-leg option positions are reflected at the maximum notional position at expiration.
The notional amounts of the Company's commodity derivatives at March 31, 2023 and December 31, 2022 were as follows:
| Commodity Notionals 1 | Mar 31, 2023 | Dec 31, 2022 | Notional Volume Unit | ||||||||
| Derivatives designated as hedging instruments: | |||||||||||
| Hydrocarbon derivatives | 8.5 | 19.2 | million barrels of oil equivalent | ||||||||
| Derivatives not designated as hedging instruments: | |||||||||||
| Hydrocarbon derivatives | 1.0 | — | million barrels of oil equivalent | ||||||||
| Power derivatives | 21.3 | — | thousands of megawatt hours |
1.Notional amounts represent the net volume of open derivative positions outstanding at the end of the period.
| Maturity Dates of Derivatives Designated as Hedging Instruments | Year | ||||
| Interest rate contracts | 2024 | ||||
| Foreign currency contracts | 2024 | ||||
| Commodity contracts | 2026 |
The following tables provide the fair value and balance sheet classification of derivative instruments at March 31, 2023 and December 31, 2022:
| Fair Value of Derivative Instruments | Mar 31, 2023 | |||||||||||||
| In millions | Balance Sheet Classification | Gross | Counterparty and Cash Collateral Netting 1 | Net Amounts Included in the Consolidated Balance Sheets | ||||||||||
| Asset derivatives | ||||||||||||||
| Derivatives designated as hedging instruments: | ||||||||||||||
| Interest rate contracts | Deferred charges and other assets | $ | 37 | $ | (35) | $ | 2 | |||||||
| Foreign currency contracts | Other current assets | 32 | (32) | — | ||||||||||
| Commodity contracts | Other current assets | 87 | (65) | 22 | ||||||||||
| Total | $ | 156 | $ | (132) | $ | 24 | ||||||||
| Derivatives not designated as hedging instruments: | ||||||||||||||
| Interest rate contracts | Other current assets | $ | 2 | $ | (2) | $ | — | |||||||
| Foreign currency contracts | Other current assets | 90 | (24) | 66 | ||||||||||
| Commodity contracts | Other current assets | 2 | — | 2 | ||||||||||
| Total | $ | 94 | $ | (26) | $ | 68 | ||||||||
| Total asset derivatives | $ | 250 | $ | (158) | $ | 92 | ||||||||
| Liability derivatives | ||||||||||||||
| Derivatives designated as hedging instruments: | ||||||||||||||
| Interest rate contracts | Other noncurrent obligations | $ | 35 | $ | (35) | $ | — | |||||||
| Foreign currency contracts | Accrued and other current liabilities | 41 | (32) | 9 | ||||||||||
| Commodity contracts | Accrued and other current liabilities | 147 | (119) | 28 | ||||||||||
| Total | $ | 223 | $ | (186) | $ | 37 | ||||||||
| Derivatives not designated as hedging instruments: | ||||||||||||||
| Interest rate contracts | Accrued and other current liabilities | $ | 2 | $ | (2) | $ | — | |||||||
| Foreign currency contracts | Accrued and other current liabilities | 32 | (24) | 8 | ||||||||||
| Commodity contracts | Accrued and other current liabilities | 2 | — | 2 | ||||||||||
| Total | $ | 36 | $ | (26) | $ | 10 | ||||||||
| Total liability derivatives | $ | 259 | $ | (212) | $ | 47 |
1.Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.
| Fair Value of Derivative Instruments | Dec 31, 2022 | |||||||||||||
| In millions | Balance Sheet Classification | Gross | Counterparty and Cash Collateral Netting 1 | Net Amounts Included in the Consolidated Balance Sheets | ||||||||||
| Asset derivatives | ||||||||||||||
| Derivatives designated as hedging instruments: | ||||||||||||||
| Interest rate contracts | Other current assets | $ | 351 | $ | (246) | $ | 105 | |||||||
| Foreign currency contracts | Other current assets | 58 | (39) | 19 | ||||||||||
| Commodity contracts | Other current assets | 199 | (148) | 51 | ||||||||||
| Total | $ | 608 | $ | (433) | $ | 175 | ||||||||
| Derivatives not designated as hedging instruments: | ||||||||||||||
| Foreign currency contracts | Other current assets | $ | 146 | $ | (50) | $ | 96 | |||||||
| Commodity contracts | Other current assets | 22 | (1) | 21 | ||||||||||
| Total | $ | 168 | $ | (51) | $ | 117 | ||||||||
| Total asset derivatives | $ | 776 | $ | (484) | $ | 292 | ||||||||
| Liability derivatives | ||||||||||||||
| Derivatives designated as hedging instruments: | ||||||||||||||
| Interest rate contracts | Accrued and other current liabilities | $ | 246 | $ | (246) | $ | — | |||||||
| Foreign currency contracts | Accrued and other current liabilities | 58 | (39) | 19 | ||||||||||
| Commodity contracts | Accrued and other current liabilities | 258 | (198) | 60 | ||||||||||
| Total | $ | 562 | $ | (483) | $ | 79 | ||||||||
| Derivatives not designated as hedging instruments: | ||||||||||||||
| Foreign currency contracts | Accrued and other current liabilities | $ | 61 | $ | (50) | $ | 11 | |||||||
| Commodity contracts | Accrued and other current liabilities | 12 | (11) | 1 | ||||||||||
| Total | $ | 73 | $ | (61) | $ | 12 | ||||||||
| Total liability derivatives | $ | 635 | $ | (544) | $ | 91 |
1.Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the Company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.
Assets and liabilities related to forward contracts, interest rate swaps, currency swaps, options and other conditional or exchange contracts executed with the same counterparty under a master netting arrangement are netted. Collateral accounts are netted with corresponding assets or liabilities, when applicable. The Company posted cash collateral of $77 million at March 31, 2023 ($80 million at December 31, 2022). No cash collateral was posted by counterparties with the Company at March 31, 2023 ($2 million at December 31, 2022).
The following tables summarize the gain (loss) of derivative instruments in the consolidated statements of income and comprehensive income for the three months ended March 31, 2023 and 2022:
| Effect of Derivative Instruments | Amount of gain (loss) recognized in OCI 1 | Amount of gain (loss) recognized in income 2 | Income Statement Classification | ||||||||||||||
| Three Months Ended | Three Months Ended | ||||||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2022 | |||||||||||||
| Derivatives designated as hedging instruments: | |||||||||||||||||
| Fair value hedges: | |||||||||||||||||
| Excluded components 3 | $ | (1) | $ | — | $ | — | $ | — | Interest expense and amortization of debt discount | ||||||||
| Cash flow hedges: | |||||||||||||||||
| Interest rate contracts | 5 | 99 | (2) | (3) | Interest expense and amortization of debt discount | ||||||||||||
| Foreign currency contracts | — | 2 | 2 | 3 | Cost of sales | ||||||||||||
| Commodity contracts | (143) | 207 | (109) | 34 | Cost of sales | ||||||||||||
| Net foreign investment hedges: | |||||||||||||||||
| Foreign currency contracts | (9) | (2) | — | — | |||||||||||||
| Excluded components 3 | 3 | 29 | — | 12 | Sundry income (expense) - net | ||||||||||||
| Total derivatives designated as hedging instruments | $ | (145) | $ | 335 | $ | (109) | $ | 46 | |||||||||
| Derivatives not designated as hedging instruments: | |||||||||||||||||
| Interest rate contracts | $ | — | $ | — | $ | — | $ | (1) | Interest expense and amortization of debt discount | ||||||||
| Foreign currency contracts | — | — | 35 | (85) | Sundry income (expense) - net | ||||||||||||
| Commodity contracts | — | — | — | 22 | Cost of sales | ||||||||||||
| Total return swap | — | — | (7) | — | Cost of sales | ||||||||||||
| Total derivatives not designated as hedging instruments | $ | — | $ | — | $ | 28 | $ | (64) | |||||||||
| Total derivatives | $ | (145) | $ | 335 | $ | (81) | $ | (18) |
1.OCI is defined as other comprehensive income (loss).
2.Pretax amounts.
3.The excluded components are related to the time value of the derivatives designated as hedges.
The following table provides the net after-tax gain (loss) expected to be reclassified from AOCL to income within the next 12 months:
| Expected Reclassifications from AOCL within the next 12 months | Mar 31, 2023 | ||||
| In millions | |||||
| Cash flow hedges: | |||||
| Interest rate contracts | $ | (7) | |||
| Commodity contracts | $ | (101) | |||
| Foreign currency contracts | $ | — | |||
| Net foreign investment hedges: | |||||
| Excluded components | $ | 3 |
NOTE 15 – FAIR VALUE MEASUREMENTS
A summary of the Company's recurring and nonrecurring fair value measurements can be found in Note 22 to the Consolidated Financial Statements included in the 2022 10-K.
Fair Value Measurements on a Recurring Basis
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis:
| Basis of Fair Value Measurements on a Recurring Basis | Mar 31, 2023 | Dec 31, 2022 | ||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
| In millions | ||||||||||||||||||||||||||
| Assets at fair value: | ||||||||||||||||||||||||||
| Cash equivalents: | ||||||||||||||||||||||||||
| Held-to-maturity securities 1 | $ | — | $ | 714 | $ | — | $ | 714 | $ | — | $ | 872 | $ | — | $ | 872 | ||||||||||
| Money market funds | — | 1,273 | — | 1,273 | — | 355 | — | 355 | ||||||||||||||||||
| Marketable securities 2 | — | 619 | — | 619 | — | 939 | — | 939 | ||||||||||||||||||
| Equity securities 3 | 18 | — | — | 18 | 10 | — | — | 10 | ||||||||||||||||||
| Nonconsolidated affiliates 4 | — | — | 7 | 7 | — | — | 7 | 7 | ||||||||||||||||||
| Debt securities: 3 | ||||||||||||||||||||||||||
| Government debt 5 | — | 641 | — | 641 | — | 622 | — | 622 | ||||||||||||||||||
| Corporate bonds | 31 | 1,116 | — | 1,147 | 35 | 1,090 | — | 1,125 | ||||||||||||||||||
| Derivatives relating to: 6 | ||||||||||||||||||||||||||
| Interest rates | — | 39 | — | 39 | — | 351 | — | 351 | ||||||||||||||||||
| Foreign currency | — | 122 | — | 122 | — | 204 | — | 204 | ||||||||||||||||||
| Commodities | 18 | 71 | — | 89 | 63 | 158 | — | 221 | ||||||||||||||||||
| Total assets at fair value | $ | 67 | $ | 4,595 | $ | 7 | $ | 4,669 | $ | 108 | $ | 4,591 | $ | 7 | $ | 4,706 | ||||||||||
| Liabilities at fair value: | ||||||||||||||||||||||||||
| Long-term debt including debt due within one year 7 | $ | — | $ | 14,239 | $ | — | $ | 14,239 | $ | — | $ | 13,875 | $ | — | $ | 13,875 | ||||||||||
| Guarantee liability 8 | — | — | 194 | 194 | — | — | 199 | 199 | ||||||||||||||||||
| Derivatives relating to: 6 | ||||||||||||||||||||||||||
| Interest rates | — | 37 | — | 37 | — | 246 | — | 246 | ||||||||||||||||||
| Foreign currency | — | 73 | — | 73 | — | 119 | — | 119 | ||||||||||||||||||
| Commodities | 68 | 81 | — | 149 | 103 | 167 | — | 270 | ||||||||||||||||||
| Total liabilities at fair value | $ | 68 | $ | 14,430 | $ | 194 | $ | 14,692 | $ | 103 | $ | 14,407 | $ | 199 | $ | 14,709 |
1.The Company's held-to-maturity securities primarily included treasury bills and time deposits.
2.The Company’s investments in marketable securities are included in “Other current assets” in the consolidated balance sheets.
3.The Company’s investments in debt securities, which are primarily available-for-sale, and equity securities are included in “Other investments” in the consolidated balance sheets.
4.Estimated asset for an investment in a limited liability company included in "Investment in nonconsolidated affiliates" in the consolidated balance sheets.
5.U.S. Treasury obligations, U.S. agency obligations, U.S. agency mortgage-backed securities and other municipalities’ obligations.
6.See Note 14 for the classification of derivatives in the consolidated balance sheets.
7.See Note 14 for information on fair value measurements of long-term debt.
8.Estimated liability for TDCC's guarantee of Sadara's debt which is included in "Other noncurrent obligations" in the consolidated balance sheets.
For equity securities calculated at net asset value per share (or its equivalent), the Company had $84 million in private market securities and $20 million in real estate at March 31, 2023 ($92 million in private market securities and $20 million in real estate at December 31, 2022). There are no redemption restrictions and the unfunded commitments on these investments were $54 million at March 31, 2023 and December 31, 2022.
For assets classified as Level 3 measurements, fair value is based on significant unobservable inputs including assumptions where there is little, if any, market activity. The level 3 asset value represents the fair value of an investment in a limited liability company, accounted for as an investment in nonconsolidated affiliates. There was no unfunded commitment on the investment at March 31, 2023 or December 31, 2022.
For liabilities classified as Level 3 measurements, fair value is based on significant unobservable inputs including assumptions where there is little, if any, market activity. The fair value of the Company’s accrued liability related to the guarantee of Sadara’s debt is in proportion to the Company’s 35 percent ownership interest in Sadara. The estimated fair value of the guarantee was calculated using a "with" and "without" method. The fair value of the debt was calculated "with" the guarantee less the fair value of the debt "without" the guarantee. The "with" and "without" values were calculated using a discounted cash flow method based on contractual cash flows as well as projected prepayments made on the debt by Sadara.
Fair Value Measurements on a Nonrecurring Basis
As part of the 2023 Restructuring Program, the Company has or will shut down a number of manufacturing facilities, corporate facilities and miscellaneous assets around the world. In the first quarter of 2023, the assets associated with this plan were written down to zero, except for one corporate facility. The remaining corporate facility, which was classified as a level 3 measurement, was written down to a fair value of $16 million using unobservable inputs. In addition, impairments of leased, non-manufacturing facilities, which were classified as Level 3 measurements, resulted in a write-down of right-of-use assets to a fair value of $9 million using unobservable inputs. The impairment charges related to the 2023 Restructuring Program, totaling $197 million, were included in "Restructuring and asset related charges - net" in the consolidated statements of income and related to Packaging & Specialty Plastics ($1 million), Industrial Intermediates & Infrastructure ($40 million), Performance Materials & Coatings ($49 million) and Corporate ($107 million).
NOTE 16 – SEGMENTS AND GEOGRAPHIC REGIONS
Dow’s measure of profit/loss for segment reporting purposes is Operating EBIT as this is the manner in which the Company's chief operating decision maker assesses performance and allocates resources. The Company defines Operating EBIT as earnings (i.e., "Income (loss) before income taxes") before interest, excluding the impact of significant items. Operating EBIT by segment includes all operating items relating to the businesses; items that principally apply to Dow as a whole are assigned to Corporate.
| Segment Information | Pack. & Spec. Plastics | Ind. Interm. & Infrast. | Perf. Materials & Coatings | Corp. | Total | ||||||||||||
| In millions | |||||||||||||||||
| Three months ended Mar 31, 2023 | |||||||||||||||||
| Net sales | $ | 6,114 | $ | 3,378 | $ | 2,276 | $ | 83 | $ | 11,851 | |||||||
| Equity in earnings (losses) of nonconsolidated affiliates | $ | 21 | $ | (73) | $ | 3 | $ | 1 | $ | (48) | |||||||
| Dow Inc. Operating EBIT 1 | $ | 642 | $ | 123 | $ | 35 | $ | (92) | $ | 708 | |||||||
| Three months ended Mar 31, 2022 | |||||||||||||||||
| Net sales | $ | 7,627 | $ | 4,524 | $ | 3,049 | $ | 64 | $ | 15,264 | |||||||
| Equity in earnings (losses) of nonconsolidated affiliates | $ | 110 | $ | 62 | $ | 3 | $ | (1) | $ | 174 | |||||||
| Dow Inc. Operating EBIT 1 | $ | 1,234 | $ | 661 | $ | 595 | $ | (71) | $ | 2,419 | |||||||
1.Operating EBIT for TDCC for the three months ended March 31, 2023 and 2022 is substantially the same as that of Dow Inc. and therefore has not been disclosed separately in the table above. A reconciliation of "Net income (loss)" to Operating EBIT is provided in the following table.
| Reconciliation of "Net income (loss)" to Operating EBIT | Three Months Ended | |||||||||||||
| In millions | Mar 31, 2023 | Mar 31, 2022 | ||||||||||||
| Net income (loss) | $ | (73) | $ | 1,552 | ||||||||||
| + Provision (credit) for income taxes | (47) | 503 | ||||||||||||
| Income (loss) before income taxes | $ | (120) | $ | 2,055 | ||||||||||
| - Interest income | 76 | 28 | ||||||||||||
| + Interest expense and amortization of debt discount | 185 | 167 | ||||||||||||
| - Significant items | (719) | (225) | ||||||||||||
| Operating EBIT | $ | 708 | $ | 2,419 |
The following tables summarize the pretax impact of significant items by segment excluded from Operating EBIT:
| Significant Items by Segment | Three Months Ended Mar 31, 2023 | |||||||||||||||||||||||||||||||
| Pack. & Spec. Plastics | Ind. Interm. & Infrast. | Perf. Mat. & Coatings | Corp. | Total | ||||||||||||||||||||||||||||
| In millions | ||||||||||||||||||||||||||||||||
| Restructuring, implementation and efficiency costs, and asset related charges - net 1 | $ | (1) | $ | (40) | $ | (67) | $ | (443) | $ | (551) | ||||||||||||||||||||||
| Litigation related charges, awards and adjustments 2 | — | (177) | — | — | (177) | |||||||||||||||||||||||||||
| Indemnification and other transaction related costs 3 | — | — | — | 9 | 9 | |||||||||||||||||||||||||||
| Total | $ | (1) | $ | (217) | $ | (67) | $ | (434) | $ | (719) |
1.Includes restructuring charges and implementation and efficiency costs associated with the Company's 2023 Restructuring Program. Also includes certain gains and losses associated with previously impaired equity investments.
2.Includes a loss associated with legacy agricultural products groundwater contamination matters. See Note 8 for additional information.
3.Primarily related to charges associated with agreements entered into with DuPont and Corteva as part of the separation and distribution which, among other matters, provides for cross-indemnities and allocations of obligations and liabilities for periods prior to, at and after the completion of the separation.
| Significant Items by Segment | Three Months Ended Mar 31, 2022 | |||||||||||||||||||||||||||||||
| Pack. & Spec. Plastics | Ind. Interm. & Infrast. | Perf. Mat. & Coatings | Corp. | Total | ||||||||||||||||||||||||||||
| In millions | ||||||||||||||||||||||||||||||||
| Digitalization program costs 1 | $ | — | $ | — | $ | — | $ | (41) | $ | (41) | ||||||||||||||||||||||
| Restructuring, implementation costs and asset related charges - net 2 | — | — | — | (10) | (10) | |||||||||||||||||||||||||||
| Russia / Ukraine conflict charges 3 | (31) | (109) | (16) | (30) | (186) | |||||||||||||||||||||||||||
| Indemnification and other transactions related costs 4 | — | — | — | 12 | 12 | |||||||||||||||||||||||||||
| Total | $ | (31) | $ | (109) | $ | (16) | $ | (69) | $ | (225) |
1.Includes costs associated with implementing the Company's Digital Acceleration program.
2.Includes costs associated with implementing the Company's 2020 Restructuring Program.
3.Asset related charges due to the Russia and Ukraine conflict. See Note 4 for additional information.
4.Primarily related to charges associated with agreements entered into with DuPont and Corteva as part of the separation and distribution which, among other matters, provides for cross-indemnities and allocations of obligations and liabilities for periods prior to, at and after the completion of the separation.
Previous: Cover and table of contents · Next: Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.